您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > PF-5274857
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
PF-5274857
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
PF-5274857图片
CAS NO:1373615-35-0
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)436.96
FormulaC20H25ClN4O3S
CAS No.1373615-35-0 (free base);
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 93 mg/mL (212.8 mM)
Water:<1 mg/mL
Ethanol: 93 mg/mL (212.8 mM)
Solubility (In vivo)Saline: 30 mg/mL
SynonymsPF-5274857; PF 5274857; PF5274857
实验参考方法
In Vitro

In vitro activity: PF-5274857 completely inhibits Shh-induced Hh pathway activity with IC50 of 2.7 nM measured by the transcriptional activity of Smo downstream gene Gli1 in MEF cells. The μ-opioid receptor is weakly inhibited by PF-5274857 with a dissociation constant of 36 μM subsequently determined in a functional assay.


Kinase Assay: HEK293 cells overexpressing human Smo (amino acids 181-787) are grown in Dulbecco's Modified Eagle's Media (DMEM) supplemented with 10% FBS, Pen–Strep, and 0.1 mg/mL hygromycin to 90% confluence. After washing with cold Dulbecco's PBS, the cell pellet is resuspended in membrane preparation buffer (50 mM Tris-HCl, pH 7.5, 250 mM sucrose with Roche complete protease cocktail) and homogenized. The homogenate is centrifuged and the cell pellet is resuspended in assay buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 25 mM MgCl2, 1 mM EDTA, and 0.1% protease-free bovine serum albumin) and homogenized in a glass tissue grinder. Total protein in the membrane preparation containing Smo is determined using the Pierce BCA protein assay. For the competitive binding assay, 100 μL of assay buffer is added to a 96-well GF/B filter plate for 10 minutes to pre-wet the filter and then removed. The following reagents are then added: 20 μL of assay buffer, 10 μL serial dilutions of compound, 20 μL of 3H-Smo antagonist (3 nM final concentration), and 50 μL of membrane preparation (40 μg total protein). The plates are incubated at room temperature for 2 hours, then washed and vacuum dried. The plates are then dried for 1 hour in a 60°C oven before the addition of 45 μL of Microscint 20 and incubated at room temperature for 30 minutes to 1 hour, then counted in a TopCount scintillation counter. The data are analyzed using GraphPad Prism software.


Cell Assay: Gli-Luc/MEF cells are grown in the knockout DMEM supplemented with 10% heat-inactive FBS, 2 mM l-glutamine, and 0.55 mM β-mercaptoethanol until 90% confluence. On day 1, cells are trypsinized and seeded into white 384-well plates in 20 μL per well of OptiMEM media that is supplemented with 1% heat-inactive FBS and 1 mM sodium pyruvate at a concentration of 7,500 cells per well. Plates are incubated at 37 °C and 5% CO2 overnight. On day 2, PF-5274857 is added to the cells at a final concentration ranging from 3 μM to 50 pM at a 3-fold serial dilution followed by addition of recombinant mouse Sonic Hedgehog to a final concentration of 2 μg/mL. The cells are incubated with PF-5274857 and Shh for 48 hours at 37 °C and 5% CO2. Luciferase assays are conducted on day 4 using the Bright-Glo Luciferase Assay System. Briefly, Bright-Glo luciferase reagent (25 μL) is added to each well of the 384-well plate containing media. Plates are kept at room temperature for 5 minutes and then read on a Luminescence plate reader. The IC50 value of PF-5274857 is calculated.

In VivoPF-5274857 shows significant dose-dependent tumor growth inhibition (TGI) and induces tumor regression at high doses(>10 mg/kg)., PF-5274857 downregulates Gli1, Gli2, Ptch1, and Ptch2 gene expression levels to various degrees with maximal effects being achieved between 6 and 12 hours post-dose (Gli1 is the most sensitive gene), whereas PF-5274857 has little effect on Smo levels. In skin tissue, downregulation of Gli1 and Gli2 is also observed with a similar time course by PF-5274857. The model-derived drug concentration for half maximal inhibition of the tumor Gli1 mRNA production rate (IC50) by PF-5274857 is determined to be 8.9 nM in the Ptch+/–p53+/– medulloblastoma allograft mice, which mathematically corresponds to tumor regression of 119% TGI after 6 days of plasma exposure at this concentration. In the Ptch+/–p53–/– medulloblastoma allograft mice, the IC50 value is estimated to be 3.5 nM, consistent with the Ptch+/–p53+/– results. PF-5274857 is also able to cross the blood–brain barrier in rats within 4 hours post-dose.
Animal modelSCID-beige mice bearing primary Ptch+/–p53+/– or Ptch+/–p53–/– medulloblastoma tumor
Formulation & DosageDissolved in 0.5% methylcellulose; 30 mg/kg; Oral administration
References

Mol Cancer Ther. 2012 Jan;11(1):57-65.